Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Considering Obesity Drug Coverage Under Medicare

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency is "open" to considering coverage of obesity drugs in light of a recent change to its obesity policy, but seeks comment on how it can legally do so, given the prohibition of weight loss drug coverage under the Medicare Modernization Act.

You may also be interested in...



Acomplia Pricing Likely To Follow Statin Model, Sanofi Says

Sanofi is considering a range of pricing options for the weight-loss/smoking cessation agent, company says; price will ultimately depend on labeling. Statin model would be appropriate if Sanofi can position the drug as long-term therapy to reduce adverse health outcomes.

Acomplia Pricing Likely To Follow Statin Model, Sanofi Says

Sanofi is considering a range of pricing options for the weight-loss/smoking cessation agent, company says; price will ultimately depend on labeling. Statin model would be appropriate if Sanofi can position the drug as long-term therapy to reduce adverse health outcomes.

USP Medicare Formulary Classes Should Use Mechanism Of Action, PhRMA Says

Subclasses should be based on other clinically relevant pharmacological characteristics, PhRMA tells USP pharmaceutical manufacturers forum. There should be enough classes to include the top 200 drugs for each of three Medicare subpopulations, PhRMA says.

Related Content

Topics

UsernamePublicRestriction

Register

PS060309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel